Short interest for DermTech gives investors a sense of the degree to which investors are betting on the decline of DermTech's stock. Short interest data is updated every two weeks.

DermTech Stock (NASDAQ:DMTK), Short Interest Report

DermTech

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACIC

ADIL

ARVN

BIVI

CRDF

DCFC

DELL

DMTK

DTIL

ESTC

EVBG

GRTS

HLTH

HUMA

JAGX

JAKK

LIFW

MINM

NTAP

NYCB

OPRA

RDNT

REAL

RGNX

RILY

RMBS

ROOT

RPAY

SANA

SCLX

SENS

SIDU

SOUN

TTEC

VANI

VLCN

VTYX

XPOF

YMAB

Shares of  Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ALLO

AMCX

ATGL

AVDX

BHIL

BILL

BOOM

BSFC

CVRX

CYTO

DOCN

DRIO

DRMA

EDIT

EIGR

ENGN

ENLV

EXPE

FIGS

FNKO

FOXF

FTNT

HIPO

HOWL

INSG

LILM

MCRB

MERC

NEXI

NLOP

NVOS

OTLY

PBLA

PCTY

PRLB

PUYI

QRTEA

RDFN

RXRX

SYRA

TNON

TRUP

UDMY

VIVK

VSME

Gainers


	Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.


Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

AAPL

ARBB

BDRX

EZGO

IFRX

INVO

MCAF

RVSN

SECO

Gainers

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

Why DigitalOcean Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

DermTech Inc

Craig-Hallum analyst Alexander Nowak assigned a Buy rating to the stock today. The company's shares closed last Friday at $1.27. According to TipRa...

Craig-Hallum Releases a Buy Rating on DermTech (DMTK)

DermTech Q4 2023 Earnings Preview

DermTech GAAP EPS of -$0.56 in-line, revenue of $3.92M misses by $0.11M

DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript

LVTX, VIEW and LASE among pre-market losers

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on DermTech (DMTK – Research Report), with a price target of $3....

DermTech (DMTK) Receives a Buy from Lake Street

MTC , ENCP and MINM among mid-day movers

In a report released today, Mark Massaro from BTIG maintained a Buy rating on DermTech (DMTK – Research Report), with a price target of $2.00. The ...

BTIG Remains a Buy on DermTech (DMTK)

DermTech exploring strategic alternatives, cutting 56% of staff

DermTech (DMTK – Research Report) received a Hold rating and price target from BTIG analyst Mark Massaro today. The company's shares closed yesterd...

DermTech (DMTK) was downgraded to a Hold Rating at BTIG

BETS

COCH

DMTKW

ENCP

ESAC

GAME

GRFS

LASE

LVTX

RMCO

RNLX

SMFL

SMXT

VIEW

Press Releases

DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay

DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types

DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations

DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

DermTech Reports Fourth-Quarter 2023 Financial Results

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

AIM ImmunoTech

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Biora Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Forte Biosciences

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Galecto

GlycoMimetics

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Kala Bio

Lisata Therapeutics

Lumos Pharma

MEI Pharma

Nanoviricides

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics

Orgenesis

BiomX

PharmaCyte Biotech

Serina Therapeutics

Synlogic

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Unity Biotechnology

Vincerx Pharma

Exagen

Lake Street

Stephens & Co.

BTIG

TD Cowen

-

-

-

-

-

-

-

-

-

-

-

-

-

-

DermTech Stock (NASDAQ:DMTK), Short Interest Report

People Also Watch